Skip to content

Fix reorder columns #104

Fix reorder columns

Fix reorder columns #104

GitHub Actions / Unit Tests Summary failed Jul 10, 2024 in 0s

3 fail, 88 skipped, 250 pass in 59s

341 tests   250 ✅  59s ⏱️
136 suites   88 💤
  1 files      3 ❌

Results for commit dfd86b9.

Annotations

Check warning on line 0 in tables_ADA_adat01

See this annotation in the file changed.

@github-actions github-actions / Unit Tests Summary

tables_ADA_adat01.qmd_result_v1_development (tables_ADA_adat01) failed

tlg.catalog.pkg.Rcheck/tests/testthat/junit-result.xml [took 0s]
Raw output
Snapshot of code has changed (variant 'development'): ('test-tables-ADA-adat01.R:1:1')
Snapshot of code has changed (variant 'development'):
old[3:24] vs new[3:24]
  Output
    Baseline Prevalence and Incidence of Treatment Emergent ADA
    
-   —————————————————————————————————————————————————————————————————————————————————————————————————————————————————
+   ———————————————————————————————————————————————————————————————————————————————————————————————————————————————————
-                                                  A: Drug X    C: Combination   <Missing>   B: Placebo   All Drug X 
+                                                    A: Drug X    C: Combination   <Missing>   B: Placebo   All Drug X 
-                                                   (N=134)        (N=132)         (N=0)      (N=134)       (N=266)  
+                                                     (N=134)        (N=132)         (N=0)      (N=134)       (N=266)  
-   —————————————————————————————————————————————————————————————————————————————————————————————————————————————————
+   ———————————————————————————————————————————————————————————————————————————————————————————————————————————————————
-   Baseline Prevalence of ADAs                                                                                      
+   Baseline Prevalence of ADAs                                                                                        
-     Baseline evaluable patients                     134            132             0           0            266    
+     Baseline evaluable patients                       134            132             0           0            266    
-   Patient with a positive sample at baseline     63 (47.0%)     64 (48.5%)         0           0        127 (47.7%)
+     Patient with a positive sample at baseline     63 (47.0%)     64 (48.5%)         0           0        127 (47.7%)
-   Patient with no positive samples at baseline       71             68             0           0            139    
+     Patient with no positive samples at baseline       71             68             0           0            139    
-   Incidence of Treatment Emergent ADAs                                                                             
+   Incidence of Treatment Emergent ADAs                                                                               
-     Post-baseline evaluable patients                134            132             0           0            266    
+     Post-baseline evaluable patients                  134            132             0           0            266    
-   Patient positive for Treatment Emergent ADA        0              0              0           0             0     
+     Patient positive for Treatment Emergent ADA        0              0              0           0             0     
-   Treatment-induced ADA                              0              0              0           0             0     
+       Treatment-induced ADA                            0              0              0           0             0     
-   Treatment-enhanced ADA                             0              0              0           0             0     
+       Treatment-enhanced ADA                           0              0              0           0             0     
-   Patient negative for Treatment Emergent ADA        0              0              0           0             0     
+     Patient negative for Treatment Emergent ADA        0              0              0           0             0     
-   Treatment unaffected                               0              0              0           0             0     
+       Treatment unaffected                             0              0              0           0             0     
-   —————————————————————————————————————————————————————————————————————————————————————————————————————————————————
+   ———————————————————————————————————————————————————————————————————————————————————————————————————————————————————
    
    ADA = Anti-Drug Antibodies (is also referred to as ATA, or Anti-Therapeutic Antibodies) Baseline evaluable patient = a patient with an ADA assay result from a baseline sample(s)
      Post-baseline evaluable patient = a patient with an ADA assay result from at least one post-baseline sample Number of patients positive for Treatment Emergent

* Run `testthat::snapshot_accept('development/tables-ADA-adat01')` to accept the change.
* Run `testthat::snapshot_review('development/tables-ADA-adat01')` to interactively review the change.

Check warning on line 0 in tables_ADA_adat04a

See this annotation in the file changed.

@github-actions github-actions / Unit Tests Summary

tables_ADA_adat04a.qmd_result_v1_development (tables_ADA_adat04a) failed

tlg.catalog.pkg.Rcheck/tests/testthat/junit-result.xml [took 0s]
Raw output
Snapshot of code has changed (variant 'development'): ('test-tables-ADA-adat04a.R:1:1')
Snapshot of code has changed (variant 'development'):
old[4:27] vs new[4:27]
    Baseline Prevalence and Incidence of Treatment Emergent NAbs
    Protocol: A: Drug X Antibody
    
-   ————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
+   —————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
-                                                       A: Drug X   C: Combination   <Missing>   B: Placebo   All Drug X
+                                                        A: Drug X   C: Combination   <Missing>   B: Placebo   All Drug X
-                                                        (N=134)       (N=132)         (N=0)      (N=134)      (N=266)  
+                                                         (N=134)       (N=132)         (N=0)      (N=134)      (N=266)  
-   ————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
+   —————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
-   Baseline Prevalence of NAbs                                                                                         
+   Baseline Prevalence of NAbs                                                                                          
-     Baseline evaluable patients for ADA                  134           132             0           0           266    
+     Baseline evaluable patients for ADA                   134           132             0           0           266    
-     Patients with a positive ADA sample at baseline      63             64             0           0           127    
+     Patients with a positive ADA sample at baseline       63             64             0           0           127    
-   Patients with a positive NAb sample at baseline         0             0              0           0            0     
+     Patients with a positive NAb sample at baseline        0             0              0           0            0     
-   Patient with no positive NAb samples at baseline        0             0              0           0            0     
+     Patient with no positive NAb samples at baseline       0             0              0           0            0     
-   Incidence of Treatment Emergent NAbs                                                                                
+   Incidence of Treatment Emergent NAbs                                                                                 
-     Post-baseline evaluable patients for ADA             134           132             0           0           266    
+     Post-baseline evaluable patients for ADA              134           132             0           0           266    
-     Patients positive for ADA                            66             59             0           0           125    
+     Patients positive for ADA                             66             59             0           0           125    
-   Patients positive for Treatment Emergent NAb            0             0              0           0            0     
+     Patients positive for Treatment Emergent NAb           0             0              0           0            0     
-   Treatment-induced NAb                                   0             0              0           0            0     
+     Treatment-induced NAb                                  0             0              0           0            0     
-   Treatment-enhanced NAb                                  0             0              0           0            0     
+     Treatment-enhanced NAb                                 0             0              0           0            0     
-   Patients negative for NAb                               0             0              0           0            0     
+     Patients negative for NAb                              0             0              0           0            0     
-   Treatment unaffected                                    0             0              0           0            0     
+     Treatment unaffected                                   0             0              0           0            0     
-   ————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
+   —————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
    
    NAb = Neutralizing Antibodies ADA = Anti-Drug Antibodies (is also referred to as ATA, or Anti-Therapeutic Antibodies) Baseline evaluable patient for ADA = a patient with an ADA assay result from a baseline sample(s)
      Baseline evaluable patient for NAb = a patient with a NAb assay result from a baseline sample(s)

* Run `testthat::snapshot_accept('development/tables-ADA-adat04a')` to accept the change.
* Run `testthat::snapshot_review('development/tables-ADA-adat04a')` to interactively review the change.

Check warning on line 0 in tables_ADA_adat04b

See this annotation in the file changed.

@github-actions github-actions / Unit Tests Summary

tables_ADA_adat04b.qmd_result_v1_development (tables_ADA_adat04b) failed

tlg.catalog.pkg.Rcheck/tests/testthat/junit-result.xml [took 0s]
Raw output
Snapshot of code has changed (variant 'development'): ('test-tables-ADA-adat04b.R:1:1')
Snapshot of code has changed (variant 'development'):
old[4:24] vs new[4:24]
    Baseline Prevalence and Incidence of Neutralizing Antibodies (NAbs)
    Protocol: A: Drug X Antibody
    
-   ————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
+   —————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
-                                                       A: Drug X   C: Combination   <Missing>   B: Placebo   All Drug X
+                                                        A: Drug X   C: Combination   <Missing>   B: Placebo   All Drug X
-                                                        (N=134)       (N=132)         (N=0)      (N=134)      (N=266)  
+                                                         (N=134)       (N=132)         (N=0)      (N=134)      (N=266)  
-   ————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
+   —————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
-   Baseline Prevalence of NAbs                                                                                         
+   Baseline Prevalence of NAbs                                                                                          
-     Baseline evaluable patients for ADA                  134           132             0           0           266    
+     Baseline evaluable patients for ADA                   134           132             0           0           266    
-     Patients with a positive ADA sample at baseline      63             64             0           0           127    
+     Patients with a positive ADA sample at baseline       63             64             0           0           127    
-   Patients with a positive NAb sample at baseline         0             0              0           0            0     
+     Patients with a positive NAb sample at baseline        0             0              0           0            0     
-   Patients with no positive NAb sample at baseline        0             0              0           0            0     
+     Patients with no positive NAb sample at baseline       0             0              0           0            0     
-   Incidence of NAbs                                                                                                   
+   Incidence of NAbs                                                                                                    
-     Post-baseline evaluable patients for ADA             134           132             0           0           266    
+     Post-baseline evaluable patients for ADA              134           132             0           0           266    
-     Patients positive for ADA                            66             59             0           0           125    
+     Patients positive for ADA                             66             59             0           0           125    
-   Patients positive for NAb                               0             0              0           0            0     
+     Patients positive for NAb                              0             0              0           0            0     
-   Patients negative for NAb                              134           132             0           0           266    
+     Patients negative for NAb                             134           132             0           0           266    
-   ————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
+   —————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
    
    NAb = Neutralizing Antibodies ADA = Anti-Drug Antibodies (is also referred to as ATA, or Anti-Therapeutic Antibodies) Baseline evaluable patient for ADA = a patient with an ADA assay result from a baseline sample(s) Baseline evaluable patient for NAb = a patient with a NAb assay result from a baseline sample(s) Post-baseline evaluable patient for ADA = a patient with an ADA assay result from at least one post-baseline sample Post-baseline evaluable patient for NAb = a patient with a NAb assay result from at least one post-baseline sample Number of patients positive for ADA = the number of post-baseline evaluable patients for ADA determined to have Treatment Emergent ADA during the study period.
    Number of patients positive for NAb = the number (and percentage) of post-baseline evaluable patients for ADA determined to have at least one positive post-baseline NAb result during the study period. Number of patients negative for NAb = number of post-baseline evaluable patients with all negative post-baseline NAb results.

* Run `testthat::snapshot_accept('development/tables-ADA-adat04b')` to accept the change.
* Run `testthat::snapshot_review('development/tables-ADA-adat04b')` to interactively review the change.